Pulmatrix (NASDAQ:PULM) Stock Passes Below Fifty Day Moving Average – What’s Next?

Posted by James Quigley on Jun 6th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.32 and traded as low as $1.22. Pulmatrix shares last traded at $1.32, with a volume of 13,316 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Get Our Latest Analysis on Pulmatrix

Pulmatrix Stock Up 0.8%

The firm has a 50-day moving average of $1.31 and a two-hundred day moving average of $2.36. The stock has a market capitalization of $4.85 million, a price-to-earnings ratio of -1.08 and a beta of 1.95.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix as of its most recent SEC filing. Institutional investors and hedge funds own 11.84% of the company’s stock.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).